Cariprazine is a D2 and D3 receptor partial agonist, with high selectivity towards the D3 receptor. Cariprazine exhibits high affinity for the D3 (Ki=0.085 nM) and D2 (Ki=0.49 nM) receptors, and moderate affinity for the 5-HT1A receptor (Ki=2.6 nM). Cariprazine has lower affinity at human and rat hippocampal 5-HT1A receptors (pKi 8.59 and 8.34, respectively) and demonstrates low intrinsic efficacy. Administration of Cariprazine (30 µg/kg) reduces the striatal uptake of both radioligands to the level of nonspecific binding compared with baseline PET measurements.
|Solubility (25°C)||DMSO 10 mM|
Powder -20°C 3 years ; 4°C 2 years
In solvent -80°C 6 months ; -20°C 1 month
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
 Yonglin Gao, et al. Pharmacol Res Perspect. Cariprazine Exerts Antimanic Properties and Interferes With Dopamine D2 Receptor β-arrestin Interactions
 Nicholas Seneca, et al. Psychopharmacology (Berl). Occupancy of Dopamine D₂ and D₃ and Serotonin 5-HT₁A Receptors by the Novel Antipsychotic Drug Candidate, Cariprazine (RGH-188), in Monkey Brain Measured Using Positron Emission Tomography
 Bela Kiss, et al. J Pharmacol Exp Ther. Cariprazine (RGH-188), a Dopamine D(3) Receptor-Preferring, D(3)/D(2) Dopamine Receptor Antagonist-Partial Agonist Antipsychotic Candidate: In Vitro and Neurochemical Profile
|Related Dopamine Receptor Products|
TAK-906 is a peripherally restricted, non-BBB permeable molecule that targets the posterior region of the stomach and vomiting center for the study of gastric cramps.
LY3154885 is an orally active dopamine D1 receptor orthosteric modulator (PAM).
ONC206 is a selective antagonist of dopamine D2-like receptor (DRD2) and has broad-spectrum anti-tumor activity.
Trifluoperazine is an FDA-approved antipsychotic drug for schizophrenia. It is an inhibitor of calmodulin (CaM) and Dopamine D2 receptor with an IC50 value of 1.2 nM for D2 receptor.
Tiapride is a drug that selectively blocks D2 and D3 dopamine receptors in the brain and is used to treat a variety of neurological and psychiatric disorders.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.